Denmark aims to lead the way in the new science of epigenetics  

Two investors have put DKK 9m into a new company called EpiTherapeutics, a spin-off from the Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen
Epigenetics is one of the hottest areas in biotech research these days, and Denmark is positioning itself for a leading role in its development. The Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen has spun out a new biotech company called EpiTherapeutics which is headed by BRIC's director Professor Kristian Helin.
EpiTherapeutics is funded by Novo which has put DKK 5m (USD 900,000) into the company, and Seed Capital Denmark which has provided DKK 4m (USD 720,000). The science of epigenetics is concerned with unravelling the mechanisms which regulate the activity of genes, in order to cast light on how cells differentiate into e.g. liver cells, brain cells or cancer cells.
According to EpiTherapeutics' website, the company's primary focus is on developing clinical applications in the oncology area, although potential applications span a wide range of indications. The company's development programmes in the field of epigenetics will focus on enzymes involved in regulating the transcription process involved in cancer.
Professor Helin told professional journal Ingeniøren (The Engineer): "We hope that we can identify some inhibitors during the next six months so that we can test them in tissue models over the course of a year, and that we can further develop them for testing in humans in three years."
Link > EpiTherapeutics         

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×